However, the HEAL randomised controlled trial of high dose EPO for perinatal asphyxia and encephalopathy in term infants did not lower risk of death or neurodevelopmental impairment and was associated with a higher risk of adverse events (22). The gene discussed is EPO; the disease is Encephalopathy.